Vinod A Pullarkat, M.D.
American Board of Internal Medicine
Royal Colleges of Physicians (UK), 1997
American Board of Hematology, 2000
American Board of Medical Oncology, 2000
1992, M.D., Calicut Medical College, University of Calicut, Kerala, India
MRCP, Royal Colleges of Physicans of United Kingdom
2002-2003, City of Medical Center, Duarte, California
1997-2000, University of Southern California, Los Angeles, California
1992-1994, Calicut Medical College, India
1995-1997, New York Methodist Hospital, Brooklyn, New York
1994-1995, New York Methodist Hospital, Brooklyn, New York
1991-1992, Calicut Medical College, University of Calicut, Kerala, India
2017-present, Professor, Hematology and Hematopoietic Cell Transplantation, City of Hope
2014-2016, Associate Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope
2011-2013, Associate Member, Edythe and Eli Broad Center for Stem Cell Research and Regenerative Medicine, USC
2011-2013, Medical Director, Stem Cell Processing Laboratory, Keck School of Medicine of USC
2011-2013, Medical Director, Hematopoietic Stem Cell Transplantation. Keck School of Medicine of USC
2011-2013, Associate Professor of Clinical Medicine, Keck School of Medicine of USC
Member, USC Norris Comprehensive Cancer Center
2009-2010, Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2003-2009, Assistant Professor, Division of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2002-2003, Clinical Instructor, City of Hope, Duarte, California
2000-2002, Clinical Instructor in Medicine, Division of Hematology, University of Southern California School of Medicine and Attending Physician, Los Angeles County + USC Medical Center, Los Angeles
Member, Royal Colleges of Physicians of the United Kingdom
Member, European Hematology Association
Member, American Society of Hematology
Member, American Society of Blood and Marrow Transplantation
Member, SouthWest Oncology Group
- Pullarkat V, Lacayo NJ, Jabbour E et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discovery 2021 (in press)
- DiNardo CD, Jonas BA, Pullarkat V et al. HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/32786187/" Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
- Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, Zhang B, Nguyen DQ, Aldoss I, Ghoda L, Budde E, Pichiorri F, Rosen S, Forman SJ, Marcucci G, Pullarkat V. The Bcl-2 inhibitor venetoclax inhibits Mrf2 antioxidant pathway activation induced by hypomethylating agents in AML J Cell Physiol. 2019 Aug;234(8):14040-14049. doi: 10.1002/jcp.28091. Epub 2019 Jan 8.
- Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13
- Malki MMA, Song JY, Yang D, Cao T, Aldoss I, Mokhtari S, Dadwal S, Marcucci G, Karanes C, Snyder D, Nademanee A, Forman SJ, Nakamura R, Pullarkat V. Iron overload is associated with delayed engraftment and increased non relapse mortality in recipients of umbilical cord blood transplantation Biol Blood Marrow Transplant. 2020 Sep;26(9):1697-1703. doi: 10.1016/j.bbmt.2020.06.002. Epub 2020.
- Sandhu KS, Dadwal S, Yang D, Mei M, Palmer J, Salhotra A, Al Malki M, Aribi A, Ali H, Khaled S, Forman SJ, Snyder D, Nakamura R, Stein AS, Marcucci G, Aldoss I, Pullarkat V. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2020 Dec;26(12):e322-e327. doi: 10.1016/j.bbmt.2020.08.027. Epub 2020